Novo Nordisk (NOVOB DC) and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Novo Nordisk's partnership with Vivtex represents a significant strategic move to advance its oral drug delivery capabilities for obesity and diabetes treatments.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

German Chancellor Merz says he wants to continue successful cooperation with China, adding that they need orderly market access and fair competition

Uber (UBER) and Joby (JOBY) launch Uber Air electric air taxi booking in app

Novo Nordisk (NOVOB DC) and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

OPEC+ at March 1st meeting to consider 137,000 bpd oil output increase for April

USTR Greer says the US has been in touch with trade partners to explain how replacement tariffs will go along with current trade deals, tariffs will go up to 15% for some countries

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront consideration, research funding and milestone payments totalling up to USD 2.1bln, and tiered royalties on future product sales.
Context

The substantial financial commitment indicates confidence in future product potential, which could enhance Novo Nordisk's market position and drive revenue growth. Watch for market reactions around Novo Nordisk's stock, especially within the broader health and biotech sectors, as this collaboration could inspire further consolidation or partnerships.

Related headlines

The whole workspace, free to try.

Try it free